These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 22304659)

  • 41. Development and optimization of dextromethorphan hydrobromide oral disintegrating tablets: effect of formulation and process variables.
    Mostafa HF; Ibrahim MA; Sakr A
    Pharm Dev Technol; 2013; 18(2):454-63. PubMed ID: 22881389
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Formulation, development, and performance evaluation of metoclopramide HCl oro-dispersible sustained release tablet.
    Kasliwal N; Negi JS; Jugran V; Jain R
    Arch Pharm Res; 2011 Oct; 34(10):1691-700. PubMed ID: 22076769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion.
    Gryczke A; Schminke S; Maniruzzaman M; Beck J; Douroumis D
    Colloids Surf B Biointerfaces; 2011 Sep; 86(2):275-84. PubMed ID: 21592751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Microwave-Assisted Development of Orally Disintegrating Tablets by Direct Compression.
    Kande KV; Kotak DJ; Degani MS; Kirsanov D; Legin A; Devarajan PV
    AAPS PharmSciTech; 2017 Aug; 18(6):2055-2066. PubMed ID: 27995465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spray dried excipient base: a novel technique for the formulation of orally disintegrating tablets.
    Mishra DN; Bindal M; Singh SK; Vijaya Kumar SG
    Chem Pharm Bull (Tokyo); 2006 Jan; 54(1):99-102. PubMed ID: 16394558
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Formulation and evaluation of floating tablet of H2-receptor antagonist.
    Kesarla RS; Vora PA; Sridhar BK; Patel G; Omri A
    Drug Dev Ind Pharm; 2015; 41(9):1499-511. PubMed ID: 25243639
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
    Maghsoodi M; Sadeghpoor F
    Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Torsemide Fast Dissolving Tablets: Development, Optimization Using Box-Bhenken Design and Response Surface Methodology, In Vitro Characterization, and Pharmacokinetic Assessment.
    El-Shenawy AA; Ahmed MM; Mansour HF; Abd El Rasoul S
    AAPS PharmSciTech; 2017 Aug; 18(6):2168-2179. PubMed ID: 28050711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Organic solution versus aqueous dispersion of Eudragit RS in preparation of sustained release microparticles of theophylline using spray drying.
    Garekani HA; Moghaddam ZF; Sadeghi F
    Colloids Surf B Biointerfaces; 2013 Aug; 108():374-9. PubMed ID: 23602991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tannate complexes of antihistaminic drug: sustained release and taste masking approaches.
    Rahman Z; Zidan AS; Berendt RT; Khan MA
    Int J Pharm; 2012 Jan; 422(1-2):91-100. PubMed ID: 22037447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. QbD approach of rapid disintegrating tablets incorporating indomethacin solid dispersion.
    Sammour OA; Hammad MA; Zidan AS; Mowafy AG
    Pharm Dev Technol; 2011 Jun; 16(3):219-27. PubMed ID: 20163325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Application of a quality-by-design approach for utilizing sodium stearyl fumarate as a taste-masking agent in dextromethorphan hydrobromide orally disintegrating tablets.
    Mahrous GM; Ibrahim MA; Mostafa HF; Elzayat EM
    Pharm Dev Technol; 2019 Jul; 24(6):711-719. PubMed ID: 30714850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, development and in-vitro evaluation of diclofenac taste-masked orodispersible tablet formulations.
    Guhmann M; Preis M; Gerber F; Pöllinger N; Breitkreutz J; Weitschies W
    Drug Dev Ind Pharm; 2015 Apr; 41(4):540-51. PubMed ID: 24495274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preparation and evaluation of orally disintegrating tablets containing taste masked microparticles of acetaminophen.
    Ikeuchi-Takahashi Y; Ito S; Itokawa A; Ota M; Onuki Y; Hidaka S; Onishi H
    Pharmazie; 2020 Jan; 75(1):2-6. PubMed ID: 32033625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets.
    Shoukri RA; Ahmed IS; Shamma RN
    Eur J Pharm Biopharm; 2009 Sep; 73(1):162-71. PubMed ID: 19406232
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and evaluation of cetirizine HCl taste-masked oral disintegrating tablets.
    Douroumis DD; Gryczke A; Schminke S
    AAPS PharmSciTech; 2011 Mar; 12(1):141-51. PubMed ID: 21181510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Design, optimization and evaluation of domperidone coevaporates.
    Nagarsenker MS; Garad SD; Ramprakash G
    J Control Release; 2000 Jan; 63(1-2):31-9. PubMed ID: 10640578
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fabrication and evaluation of taste masked resinate of risperidone and its orally disintegrating tablets.
    Shukla D; Chakraborty S; Singh S; Mishra B
    Chem Pharm Bull (Tokyo); 2009 Apr; 57(4):337-45. PubMed ID: 19336927
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative study of different approaches for preparation of chlorzoxazone orodispersible tablets.
    Moqbel HA; ElMeshad AN; El-Nabarawi MA
    Drug Dev Ind Pharm; 2017 May; 43(5):742-750. PubMed ID: 27534668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and characterization of metformin hydrochloride- and glyburide-containing orally disintegrating tablets.
    Gulsun T; Akdag Y; Izat N; Cetin M; Oner L; Sahin S
    Pharm Dev Technol; 2020 Oct; 25(8):999-1009. PubMed ID: 32431206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.